WALTHAM, Mass., October 11, 2019 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5 th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET.

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on
the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other
gut-derived diseases. The Company has built a pipeline of novel small-molecules and live
biotherapeutics with lead programs to address the significant unmet patient needs associated with
Parkinson’s Disease and Autism Spectrum Disorder.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.